Boehringer launches Equisolon^®, the first oral prednisolone for horses

Boehringer Ingelheim has launched Equisolon^® 33 mg/g oral powder, the first licensed oral prednisolone for the alleviation of inflammation associated with recurrent airway obstruction, otherwise known as heaves, in horses.

Equisolon should be used in combination with environmental measures to treat RAO.

Equisolon complements the Boehringer Ingelheim equine respiratory portfolio, which also includes Sputolosin^® and Ventipulmin^®.

“Oral glucocorticoids are sometimes necessary for treating the inflammation associated with RAO. We feel it is important that when our customers need to use prednisolone for their cases, there is an equine specific product available to them that is easy to dispense and administer,” says Clare Turnbull, equine brand and technical manager at Boehringer Ingelheim.

For further information on Equisolon, contact your Boehringer Ingelheim equine representative or call +44 (0)1344 746959.